Peyronie's Disease Clinical Trial
Official title:
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effectiveness of AA4500 Administered Two Times a Week for Up to Three Treatment Cycles (2 x 3) in Subjects With Peyronie's Disease
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
A Phase 2b randomized, double-blind, placebo-controlled study of AA4500 in the treatment of
subjects with Peyronie's disease.
During the screening period, subjects had a physical examination including body weight and
height, vital sign measurements, a 12-lead electrocardiogram (ECG), and clinical laboratory
testing. Medical history, prior and concomitant medications, and demographic data were
recorded.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01685437 -
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
|
Phase 3 | |
| Completed |
NCT01430169 -
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
|
Phase 2 | |
| Completed |
NCT01221597 -
Study of AA4500 in the Treatment of Peyronie's Disease
|
Phase 3 | |
| Recruiting |
NCT05108558 -
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
|
Phase 4 | |
| Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
| Recruiting |
NCT03767452 -
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
|
Phase 4 | |
| Completed |
NCT02267460 -
An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
|
Phase 3 | |
| Completed |
NCT01221623 -
Study of AA4500 in the Treatment of Peyronie's Disease
|
Phase 3 | |
| Completed |
NCT02298829 -
Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease
|
||
| Completed |
NCT01243411 -
A Study of AA4500 in Men With Peyronie's Disease
|
Phase 3 | |
| Completed |
NCT01578473 -
Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease
|
Phase 1 | |
| Not yet recruiting |
NCT05855070 -
Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease
|
N/A | |
| Completed |
NCT02072018 -
Peyronie's Disease Treatment Protocol
|
Phase 1 | |
| Terminated |
NCT05873595 -
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
|
||
| Active, not recruiting |
NCT04786106 -
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
|
Phase 4 | |
| Completed |
NCT00812838 -
H-22411: BOTOX® for Peyronie's Disease
|
Phase 2 | |
| Completed |
NCT02395029 -
Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD
|
Phase 1 |